In accordance with the international recommendations, bone formation marker procollagen type I intact N-terminal propeptide (P1NP) and bone resorption marker collagen type I C-telopeptide (CTX) were generated using commercially available chemiluminescence protocols (Immunodiagnostics Systems, The Boldens, United Kingdom), as conducted previously (Wherry et al., 2019)
Foundayos approval was backed by a phase 3 program called the ATTAIN trials, which enrolled over 4,500 participants across two large global studies
Second, our analysis did not evaluate differences in adverse events between subcutaneous and oral semaglutide formulations
User's guide to mechanism of action and clinical use of GLP-1 receptor agonists
Phase 3 trials run longer (typically 72 weeks or more) to confirm that the weight loss is sustained and that no long-term safety issues emerge
You can see theres a little window here